Fosamac 150mg Injection

Fosamac 150mg Injection is an antimetic medication that is used to prevent nausea and vomiting caused by the chemotherapy and cancer treatments.

It contains Fosaprepitant Dimeglumine salt that works by blocking the action of substance P, a natural substance in the brain that triggers the nausea and vomiting symptoms.​​​

• Prevent Nausea and Vomiting

Like any other chemical-based medication, Fosamac 150mg Injection side effects also ranges from mild to serious. Patients are advised to seek immediate medical attention if they experience any signs of an allergic reaction, severe problems or prolonged symptoms.

• Constipation
• Headache
• Indigestion
• Heartburn
• Tiredness
• Loss of Apetite
• Hiccups
• Dizziness
• Diarrhea
• Increased Liver Enzymes

• Severe Allergic Reaction
• Unusual Bleeding
• Brusing
• Signs of Infection
• Blistering
• Severe Skin Reactions

• Fosamac 150mg Injection is administered intravenously. It can be administered either alone or with other cancer treatment therapies.
• Patients should not self-administer; it must be injected by a doctor or trained nurse. Consult a doctor for precise dosage and timing.​​
  

• Fosamac 150mg Injection contains Fosaprepitant Dimeglumine salt that works by blocking the action of substance P, a natural substance in the brain that triggers the nausea and vommiting symptoms.
• Aprepitant blocks the NK1 receptors in the central nervous system thus, blocking the the emetic signals triggered by substance P.​​
  

• Garnock-Jones, K. P. (2016). Fosaprepitant dimeglumine: a review in the prevention of nausea and vomiting associated with chemotherapy. Drugs, 76(14), 1365-1372. https://pubmed.ncbi.nlm.nih.gov/27510503/
• Colon-Gonzalez, F., & Kraft, W. K. (2010). Pharmacokinetic evaluation of fosaprepitant dimeglumine. Expert opinion on drug metabolism & toxicology, 6(10), 1277-1286. https://pubmed.ncbi.nlm.nih.gov/20795794/
• Van Belle, S. J., & Cocquyt, V. (2008). Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting. Expert Opinion on Pharmacotherapy, 9(18), 3261-3270. https://pubmed.ncbi.nlm.nih.gov/19040346/
• Xue, F., Liu, X., Qi, X., Zhou, J., & Liu, Y. (2023). The clinical research study for fosaprepitant to prevent chemotherapy-induced nausea and vomiting: A review. Advances in Clinical and Experimental Medicine, 32(6), 701-706. https://pubmed.ncbi.nlm.nih.gov/37026971/